Piloting a Remission Strategy in Type 2 Diabetes: Results of a Randomized Controlled Trial

What Was Tested

The paper reports a study of Insulin Glargine, published as a randomized controlled trial.

This trial assessed the feasibility, safety, and potential to induce remission of a short-term intensive metabolic strategy.

Who Took Part

According to the abstract, 83 participants were involved.

By PubMed's age tags, the people studied were middle-aged adults and older adults, both men and women.

A randomized, parallel, open-label pilot trial with 83 participants followed for 52 weeks.

Patients with type 2 diabetes of up to 3 years in duration.

How the Study Was Run

The design is described as randomized, open-label, parallel-group and pilot.

Because people in this Insulin Glargine study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Being open-label, the Insulin Glargine study did not mask who received what.

The Insulin Glargine group and the comparison group ran side by side rather than switching.

It is described as a pilot, a small early test of whether a larger Insulin Glargine study would be practical.

A time span of 52 weeks appears in the methods.

Participants were randomized to: (1) an 8-week intensive metabolic intervention, (2) a 16-week intensive metabolic intervention, or (3) standard diabetes care.

During the intensive intervention period, weight loss and normoglycemia were targeted using lifestyle approaches and treatment with metformin, acarbose, and insulin glargine.

Diabetes drugs were then discontinued in the intervention groups and participants were followed for hyperglycemic relapse.

What Was Measured

The subject headings attached to it are Acarbose, Ambulatory Care, Blood Glucose, Diabetes Mellitus, Type 2, Diet, Reducing, Exercise and Feasibility Studies.

What This Means in Plain Language

The paper is a randomized, open-label and parallel-group study of Insulin Glargine in 83 participants over 52 weeks.

Results are reported in around 4 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2017 (The Journal of clinical endocrinology and metabolism), a journal based in United States.

More context: the Insulin Glargine compound page.